Geneva, Switzerland – 02 June 2009: PregLem, the Swiss biopharmaceutical company specializing in women’s reproductive medicine, is pleased to announce the appointment of Dr Suhail Nurbhai as Chief Medical Officer.
Dr Nurbhai has over 15 years’ experience in clinical research and development in the pharmaceutical industry. He spent 12 years at Pfizer where he held leading roles in the development of multiple GU/sexual health medicines, as well as building and leading the GI/GU clinical development group at the R&D headquarters in Connecticut, USA. During this time he also led the US team for NDA submission and the global team for the MAA submission of Enablex for Overactive Bladder.
Dr Nurbhai then joined Dynogen Pharmaceuticals, a start-up company specialising in developing medicines for GI and GU disorders, where he spent more than three years as Vice President and Head of Clinical Development with overall strategic and operational responsibility for all clinical programmes.
Dr Nurbhai qualified in Medicine from Dundee University in Scotland, and is a Member of the Royal College of Physicians of the United Kingdom.
Dr. Ernest Loumaye, CEO and Founder of PregLem, said: “We are delighted to welcome Dr. Nurbhai to PregLem. His strong experience and successful track record in clinical development will help drive the development and registration of PregLem’s first-in-class compounds to treat women’s reproductive health conditions.”
“I am excited to be joining PregLem at this critical stage in its development”, said Dr. Nurbhai, “PregLem is led by a highly experienced management team with a proven track record in reproductive medicine. In a short period, they have built up a strong pipeline of compounds in an upcoming therapeutic area that holds great potential for innovative products yet still enjoys limited competition. I look forward to helping to bring these important compounds to market and to help build PregLem into a leading specialty pharmaceutical company.”
PregLem is a Swiss speciality biopharmaceutical company, dedicated to the development and commercialization of a new class of drugs for women’s reproductive health conditions.
PregLem has an experienced senior management team, with a proven track record in developing, registering and commercializing reproductive health products. The company is backed by a blue chip investor base.
PregLem in-licensed ulipristal acetate from HRA Pharma to develop it for the treatment of uterine myoma (fibroids) in doses of 5 and 10 mg. HRA recently obtained a positive CHMP recommendation for approval of ulipristal acetate in emergency contraception, a significant step towards de-risking the registration of PregLem’s PGL4001 (see March 2009 press releases on www.hra.comand www.preglem.com).